Publikationen 1996 - 1999

  1. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, Schellong G: Definition of a standard-risk group in children with AML. Br J Haematol 1999;104:630-639. PM:10086807
  2. Creutzig U: Akute myeloische Leukämie im Kindesalter; in Schmoll HJ, Höffken.K., Possinger K, (eds):Kompendium Internistische Onkologie. Berlin, Springer, 1999, pp 687-698.
  3. den Boer ML, Pieters R, Kazemier KM, Janka-Schaub G, Henze G, Creutzig U, Kaspers GJ, Kearns PR, Hall AG, Pearson AD, Veerman AJ: Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia. Br J Haematol 1999;104:321-327.
  4. Graubner UB, Boos J, Creutzig U, Dorffel W, Lakomek M, Niemeyer C, Schrappe M, Spaar HJ, Belohradsky BH: [Antiinfectious prophylaxis in pediatric oncology. Work group "Quality Assurance" of Society for Pediatric Oncology and Hematology (GPOH)]. Klin Padiatr 1999;211:347-352. PM:10472574
  5. Hasle H, Arico M, Basso G, Biondi A, Cantu RA, Creutzig U, Fenu S, Fonatsch C, Haas OA, Harbott J, Kardos G, Kerndrup G, Mann G, Niemeyer CM, Ptoszkova H, Ritter J, Slater R, Stary J, Stollmann-Gibbels B, Testi AM, van Wering ER, Zimmermann M: Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia 1999;13:376-385. PM:10086728
  6. Kallage V, Müller JE, Zimmermann M, Beck JD, Ritter J, Creutzig U: Prognose, Therapierealisierung und Komplikationen bei den Nonrespondern der Studie AML-BFM 87. Klin Pädiatr 1999;211:250-259.
  7. Kallage V, Muller JE, Zimmermann M, Beck JD, Ritter J, Creutzig U: [Prognosis, treatment completion, and complications in nonresponders in the study AML-BFM87]. Klin Padiatr 1999;211:250-259. PM:10472559
  8. Kaspers GJ, Zwaan CM, Veerman AJ, Rots MG, Pieters R, Bucsky P, Domula M, Gobel U, Graf N, Havers W, Jorch N, Kabisch K, Spaar HJ, Ritter J, Creutzig U: Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study. Klin Padiatr 1999;211:239-244. PM:10472557
  9. Kern W, Büchner T, Wörmann B, Ritter J, Creutzig U, Hiddemann W: Akute Leukämien; Prognostische Faktoren und Therapiestrategien. Internist 1999;40:983-986.
  10. Reinhardt D, Pekrun A, Lakomek M, Ritter J, Creutzig U: [Primary isolated myeolosarcoma in childhood]. Klin Padiatr 1999;211:245-249. PM:10472558
  11. Reinhardt D, Pekrun A, Lakomek M, Ritter J, Creutzig U: Primäre isolierte Myelosarkome bei Kindern. Klin Pädiatr 1999;211:245-249.
  12. Reinhardt D, Pekrun A, Lakomek M, Ritter J, Creutzig U: Isolierte Myelosarkome der Haut im Kindesalter. Monatsschrift Kinderheilkunde 1999;147:346-350.
  13. Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Kaspers GJL, Hählen K, Creutzig U, Veerman AJP, Jansen G: Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood 1999;54:3121-3128.
  14. Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Kaspers GJL, Hählen K, Creutzig U, Veerman AJP, Jansen G: Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accummulation and polyglutamylation in childhood leukemia. Blood 1999;93:1677-1683.
  15. Schwartz S, Heinecke A, Zimmermann M, Creutzig U, Schoch C, Harbott J, Fonatsch C, Löffler H, Buchner T, Ludwig WD, Thiel E: Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 1999;34:85-94. PM:10350335
  16. Creutzig U, Ritter J, Boos J, Zimmermann M, Bender-Götze C, Stahnke K: Prognose von Kindern mit AML nach dem ersten Rezidiv. Klin Pädiatr 1998;210:207-211.
  17. Creutzig U, Ritter J, Zimmermann M, Boos J, Bender-Götze C, Stahnke K: Risk factors for survival in children with refractory AML treated according to AML relapse strategies. Haematol Blood Transf 1998;39:810-817.
  18. Creutzig U, Ritter J, Boos J, Zimmermann M, Bender-Gotze C, Stahnke K: [Prognosis of children with acute myelocytic leukemia after first relapse]. Klin Padiatr 1998;210:207-211. PM:9743954
  19. Creutzig U, Baumann M: Spontaneous remission in neonates with Down's syndrome and acute myelogenous leukemia - transient myeloproliferative disease. Onkologie 1998;21:184-188.
  20. Creutzig U, Bender-Götze C, Ritter J, Zimmermann M, Stollmann-Gibbels B, Körholz D, Niemeyer C: The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t. Leukemia 1998;12:652-659.
  21. den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJ: Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998;91:2092-2098. PM:9490695
  22. Dübbers A, Schulze-Westhoff P, Kurzknabe E, Creutzig U, Ritter J, Boos J: Asparaginase synthetase in paediatric acute leukemias: AML-M5 subtype shows lowest activity. Haematol Blood Transf 1998;39:530-535.
  23. Kaspers GJL, Zwaan M, Creutzig U, Ritter J, Rottier MMA, Pieters R, Veerman AJP: In vitro drug resistance in childhood acute myeloid leukemia: a preliminary analysis. Haematol Blood Transf 1998;39:491-495.
  24. Lanvers C, Wagner A, Dübbers A, Krümpelmann S, Würthwein G, Ritter J, Creutzig U, Blaschke G, Jürgens H, Boos J: Pharmakokinetics and metabolism of low-dose ATRA in children - first observations. Haematol Blood Transf 1998;39:565-569.
  25. Stahnke K, Boos J, Bender-Götze C, Ritter J, Zimmermann M, Creutzig U: Duration of first remission predicts remission rates and longterm survival in children with relapsed acute myelogenous leukemia. Leukemia 1998;12:1543-1538.
  26. Creutzig U, Ritter J, Niemeyer C, Stollmann-Gibbels B, Zimmermann M, Reinisch I, Harbott J: Down's syndrome and megakaryoblastic leukemia. Haematol Blood Transf 1997;38:754-760.
  27. Harbott J, Reinisch-Becker I, Ritterbach J, Creutzig U, Ludwig W-D, Gutjahr P, Borkhardt A, Lampert F: Karyotypic abnormalities in secondary leukemia of children. Haematol Blood Transf 1997;38:24-28.
  28. Ritter J, Creutzig U, Zimmermann M: The specific role of Idarubicin during Induction therapy of childhood AML. Haematol Blood Transf 1997;38:396-399.
  29. Schellong G, Riepenhausen M, Creutzig U, Ritter J, Harbott J, Mann G, Gadner H, for the German-Austrian Pediatric Hodgkin's Disease Group: Incidence of Secondary Leukemias After Therapy of Childhood Hodgkin's Disease Without Nitrogen-Mustard. Results of the German-Austrian Study Group. Haematol Blood Transf 1997;38:898-904.
Suchen
Benutzeranmeldung